Publications database

The recently published results of the NETTER-2 trial suggest the use of [177Lu]Lu-DOTATATE as a new standard of care in first-line therapy of patients with grade 2 or 3, well-differentiated, advanced gastroenteropancreatic neuroendocrine tumors. The NETTER-2 trial found superior median progression-free survival (22.8 mo vs. [...]

Fibroblast activation protein (FAP)-targeted imaging has emerged as a promising diagnostic tool for various oncologic and nononcologic conditions. However, the increasing employment of FAP-targeted imaging with small-molecule radiotracers mandates a standardized reporting system to ensure consistent interpretation across various clinical scenarios, especially in oncologic imaging. [...]

Many metastatic clear cell renal cell carcinomas (ccRCC) are resistant to immune checkpoint inhibitor therapies, however the mechanisms underlying sensitivity or resistance remain incompletely characterised. We demonstrate that ccRCCs in the Vhl/Trp53/Rb1 mutant mouse model are resistant to combined anti-PD-1/anti-CTLA-4 therapy alone and in combination with additional therapeutic agents that reflect current ccRCC clinical trials. [...]

Guideline-based patient educational materials (PEMs) empower patients and reduce misinformation, but require frequent updates and must be adapted to the readability level of patients. The aim is to assess whether generative artificial intelligence (GenAI) can provide readable, accurate, and up-to-date PEMs that can be subsequently translated into multiple languages for broad dissemination.The European Association of Urology (EAU) guidelines for prostate, bladder, kidney, and testicular cancer were used as the knowledge base for GPT-4 to generate PEMs. [...]